RxDoctor Payments Data

Juliet Vento

Internal Medicine · Miami, FLNPI 1326467887

Payments from drug & device makers

What this record shows

5 manufacturers reported payments, led by Novo Nordisk AS at 58.7% of the total. Reporting peaked in 2022 at $640 and has fallen 81.0% since, to $122 in 2023.

$919in general payments, 2019–2025

Across 8 payments — averaging $114.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$540
  • AbbVie$124
  • Novo Nordisk$122
  • Merck$100
  • Lilly USA, LLC$32
$735,023in research payments, 2019–2025

Across 10 payments — averaging $73,502 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$719K
  • Novartis$15K
  • E.r. Squibb & Sons, L.L.C.$312

What the payments were for

  • Consulting fees$54059%
  • Food & beverage$37941%

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS1$540
AbbVie1$124
Novo Nordisk1$122
Merck3$100
Lilly USA, LLC2$32

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$919 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida →

Other internal medicine in Miami

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →